Temporal analysis of doxorubicin-induced cardiac toxicity and hypertrophy
Abstract Doxorubicin (DOX), although effective in treating cancer, has significant cardiac side effects, which limit its clinical utility. In this study, we collected time-course transcriptomics and metabolomics data from the human cardiomyocyte cell line AC16, which we analyzed along with curated p...
Saved in:
| Main Authors: | Yu-Te Lin, Yi-Ju Lee, Wen-Wei Tseng, Zih-Hua Chen, Huai-Ching Hsieh, Ko-Hong Lin, Jin-Yu Su, An-Chi Wei |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Systems Biology and Applications |
| Online Access: | https://doi.org/10.1038/s41540-025-00545-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
by: Si-Chi Xu, et al.
Published: (2017-01-01) -
Vericiguat improves cardiac remodelling and function in rats with doxorubicin‐induced cardiomyopathy
by: Wen Chen, et al.
Published: (2025-06-01) -
Ginsenoside Rb1 ameliorates post-doxorubicin treatment myocardial hypertrophy via CaN/NFATc4/GATA4
by: Jin-Jin Chang, et al.
Published: (2025-09-01) -
Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer
by: Atefeh Ghahremanloo, et al.
Published: (2025-03-01) -
Nuclear receptor corepressor 1 represses cardiac hypertrophy
by: Chao Li, et al.
Published: (2019-09-01)